Counteracting learned non-use in chronic stroke patients with reinforcement-induced movement therapy

Table 2 Clinical outcome measures at end of treatment and at follow-up

Within-group analysis							Between-group analysis
Mean (SD) - Median 95 % confidence interval for the mean (lower and upper bound)							p-values
	End of treatment	Change from	p-values	Follow-up	Change from	p-values	Change from	Change from
	T1	baseline to T1		T2	baseline to T2		baseline to T1	baseline to T2
UE-FM
EG	38.33 (17.30) – 39	6.00 (6.31) – 4	.008	46.22 (14.96) – 52	13.89 (9.88) – 10	.004
	[25.04–51.63]	[1.15–10.85]		[34.72–57.73]	[6.29–21.48]
							.715	.037
CG	43.22 (12.62) – 44	6.33 (4.50) – 7	.008	41.78 (12.47) – 40	4.89 (4.31) – 5	.016
	[33.52–52.92]	[2.87–9.79]		[32.19–51.36]	[1.57–8.20]
CAHAI
EG	33.56 (15.08) – 36	1.00 (1.66) – 0	.125	25.11 (16.04) – 42	2.56 (4.64) – 1	.094
	[21.96–45.15]	[-0.27–2.27]		[22.78 – 47.44]	[-1.01–6.12]
							.553	.552
CG	34.22 (14.71) – 43	0.89 (2.37) – 0	.500	34.89 (14.34) – 43	1.56 (3.64) – 0	.250
	[22.91–45.53]	[-0.93–2.71]		[23.87–45.91]	[-1.25–4.36]
BI
EG	85.56 (10.90) – 88	0.22 (0.67) – 0	1.000	87.78 (8.27) – 90	2.44 (5.18) – 0	.125
	[77.18–93.93]	[-0.29–0.73]		[81.42–94.14]	[-1.53–6.42]
							1.000	.241
CG	91 (6.69) – 90	0.44 (1.33) – 0	1.000	91 (6.69) – 90	0.44 (1.33) – 0	1.000
	[85.86–96.14]	[-0.58–1.47]		[85.86–96.14]	[-0.58–1.47]
Hamilton
EG	13.89 (9.61) – 8	-0.56 (1.13) – 0	.500	13.67 (9.85) – 8	-0.78 (1.39) – 0	.250
	[6.50–21.28]	[-1.42–0.31]		[6.10–21.24]	[-1.85–0.29]
							.506	.776
CG	10.78 (10.15) – 5	-1.67 (2.83) – 0	.250	11.67 (11.87) – 5	-0.78 (3.93) – 0	.688
	[2.98–18.58]	[-3.84–0.51]		[2.54–20.79]	[-3.80–2.24]

Bold values indicate significant values (p <.05), p-values for within-group analysis were obtained with Wilcoxon signed-rank test, p-values for between-group analysis were obtained with Wilcoxon rank-sum test

ISSN: 1743-0003